BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per share of €1.08 compared to Wall Street’s estimate of 44 cents for the quarter. While that beat estimates, it’s down 42.6% year-over-year from €1.88 per share. Full-year EPS of -€2.77 was also better than the expected -€3.43.
BioNTech’s Q4 2024 revenue came in at €1.19 billion, which barely beat analysts’ estimate of €1.18 billion. Even so, it still represented a 19.6% decrease year-over-year from revenue of €1.48 billion. 2024 revenue of €2.75 billion also came in higher than the expected €2.53 billion.
Despite beating Q4 estimates, BNTX stock didn’t perform well on Monday with a 2.56% drop as of this writing. That builds on its negative start to 2025 with a 6.45% decrease and eats away at its 10.7% increase over the last 52 weeks.
BioNTech 2025 Guidance
BioNTech provided investors with a guidance update in its latest earnings report. The company expects revenue for 2025 to range from €1.7 billion to €2.2 billion. Investors aren’t happy about this outlook as it sits firmly below Wall Street’s 2025 revenue estimate of €2.53 billion.
BioNTech also expects R&D expenses of €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and Capital expenditures for operating activities of €250 million to €350 million during 2025.
Is BNTX Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for BioNTech is Strong Buy based on 10 Buy and one Hold ratings over the last three months. With that comes an average price target of $144.05, a high of $170, and a low of $120. This represents a potential 35.27% upside for BNTX stock. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
